Loading...
Please wait, while we are loading the content...
DNA Polymerase θ: A Cancer Drug Target with Reverse Transcriptase Activity
| Content Provider | MDPI |
|---|---|
| Author | Chen, Xiaojiang Pomerantz, Richard |
| Copyright Year | 2021 |
| Description | The emergence of precision medicine from the development of Poly (ADP-ribose) polymerase (PARP) inhibitors that preferentially kill cells defective in homologous recombination has sparked wide interest in identifying and characterizing additional DNA repair enzymes that are synthetic lethal with HR factors. DNA polymerase theta (Polθ) is a validated anti-cancer drug target that is synthetic lethal with HR factors and other DNA repair proteins and confers cellular resistance to various genotoxic cancer therapies. Since its initial characterization as a helicase-polymerase fusion protein in 2003, many exciting and unexpected activities of Polθ in microhomology-mediated end-joining (MMEJ) and translesion synthesis (TLS) have been discovered. Here, we provide a short review of Polθ‘s DNA repair activities and its potential as a drug target and highlight a recent report that reveals Polθ as a naturally occurring reverse transcriptase (RT) in mammalian cells. |
| Starting Page | 1146 |
| e-ISSN | 20734425 |
| DOI | 10.3390/genes12081146 |
| Journal | Genes |
| Issue Number | 8 |
| Volume Number | 12 |
| Language | English |
| Publisher | MDPI |
| Publisher Date | 2021-07-27 |
| Access Restriction | Open |
| Subject Keyword | Genes Dna Polymerase Reverse Transcriptase Rna Reverse Transcription Double-strand Break Repair Translesion Synthesis |
| Content Type | Text |
| Resource Type | Article |